Theratech begins female testosterone patch trial:
This article was originally published in Clinica
Executive Summary
Theratech has begun a Phase II study of its testosterone patch to treat younger women who have undergone hysterectomy and suffer from depleted sexual function. The study will use the patch to administer small doses of testosterone, that would normally be released by the ovaries. It will evaluate if testosterone therapy restores the patients' sexual desire, frequency and satisfaction. Theratech, based in Salt Lake City, Ohio, estimates that as many as 10 million women living in the US and Europe have undergone hysterectomy.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.